DaVita (BSP:DVAI34) FFO


BSP:DVAI34 DaVita Inc BSP:DVAI34
73 GF Score
Price R$1,214.00
GF Value R$900.41
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is DaVita FFO?

FFO (Funds from operations) only applies to REITs.

BSP:DVAI34
73GF Score
DaVita Inc BSP:DVAI34
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is DaVita (BSP:DVAI34) Overvalued in 2026?

Based on GuruFocus' analysis, DaVita stock appears to be overvalued. The current stock price of R$1,214.00 is trading 34.8% above its estimated GF Value™ of R$900.41. GuruFocus considers DaVita to be Significantly Overvalued.

Key valuation signals for BSP:DVAI34:

  • FFO:
  • GF Value™: R$900.41 vs. price of R$1,214.00 (34.8% above fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the BSP:DVAI34 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

DaVita Business Description

Address 2000 16th Street, Denver, CO, USA, 80202
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
73GF Score

Get the complete analysis for BSP:DVAI34

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

R$1,214.00
Price
R$900.41
GF Value